<DOC>
	<DOCNO>NCT01931085</DOCNO>
	<brief_summary>Triclabendazole benzimidazole compound use systemic antihelmintic veterinary practice . Triclabendazole consider second-line drug parasite use preferred agent use ineffective adverse reaction limit use . Although Triclabendazole widely use develop country treatment parasites approved FDA treatment US . It currently distribute US special arrangement FDA manufacturer individual patient approval basis . This arrangement require single patient Investigational New Drug ( IND ) obtain FDA patient require Triclabendazole . Upon approval FDA , manufacturer ( Novartis ) ship drug directly prescribe physician .</brief_summary>
	<brief_title>Compassionate Use Triclabendazole Treatment Parasites ( Prior FDA Approval ; Expanded Access Program )</brief_title>
	<detailed_description />
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Triclabendazole</mesh_term>
	<criteria>Patients diagnosis parasite whose resistance pattern indicate resistance first line agent sensitivity Triclabendazole additional drug need added regimen inadequate response exist therapy . Patients parasite sensitive Triclabendazole experience allergic adverse reaction agent prevent use . Patients parasitic disease respond treatment first line drug experience allergic adverse reaction agent prevent continue use experience relapse disease necessitates addition , substitution , secondline agent Patients qualify study use Triclabendazole study exist thus patient would otherwise access drug Anyone whose parasitic disease adequately treat available medication . Anyone allergic severe adverse reaction Triclabendazole past . Pregnant Women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>